
|Videos|May 14, 2022
Dr. William Huang on UGN-102 in non–muscle-invasive bladder cancer
Author(s)Urology Times staff
“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.
Advertisement
In this interview, recorded at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana, William C. Huang, MD, discusses the OPTIMA II and ENIVISION trials evaluating UGN-102 in non–muscle-invasive bladder cancer. Huang is professor and vice chair for clinical affairs in the Department of Urology at NYU Grossman School of Medicine in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Practical tips for AE management with the gemcitabine intravesical system
2
Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system
3
Study to assess adaptive-dosed 177Lu-DOTA-HYNIC-panPSMA in mHSPC
4
First-in-human bladder transplant demonstrates sustained function at 6 months
5












